Belimumab denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belimumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Belimumab as "Not FDA-Approved"

Belimumab (Benlysta) holds FDA approval for specific indications in systemic lupus erythematosus (SLE) and lupus nephritis. UnitedHealthcare occasionally issues a "not FDA-approved" denial when the diagnosis code on the claim does not clearly align with an approved indication, when the route of administration (intravenous vs. subcutaneous) differs from what the authorization covers, or when the prescriber's documented indication contains language that suggests off-label use. This type of denial is appealable because the FDA indication for belimumab is well-established — the core question is usually one of documentation alignment, not true regulatory status.

## Your Appeal Rights

Federal law gives you layered protections. Under ACA Section 2719 and ERISA Section 503, you are entitled to a full-and-fair internal review followed, if needed, by an independent external review through an accredited Independent Review Organization (IRO). The external-review request window is typically within four months of receiving a final adverse determination — do not let that deadline pass. An expedited review (decision within 72 hours) is available if your condition is urgent or if a standard timeline could seriously jeopardize your health.

## The Appeal Process

1. Request the complete denial letter and the UnitedHealthcare Medical/Coverage Policy for belimumab in writing. 2. File a Level 1 internal appeal within the timeframe stated on your denial notice (commonly 180 days for ERISA plans). 3. If Level 1 is upheld, request a Level 2 review or proceed directly to external review. 4. Escalate to your state Insurance Commissioner if the plan is fully insured and the IRO upholds the denial.

## Documentation to Gather

• Confirmed diagnosis: Chart notes, lab results, and specialist records that clearly establish the FDA-approved indication (e.g., active SLE meeting the relevant classification criteria as determined by your physician).
• Prescriber letter: A detailed medical-necessity letter from the treating rheumatologist or nephrologist stating the specific FDA-approved indication, explaining why belimumab is appropriate, and quoting the relevant indication language from the FDA-approved prescribing information.
• Formulary and authorization record: Copy of the original prior-authorization approval (if any) and the pharmacy or infusion claim to confirm route and indication were coded consistently.
• Supporting guidelines: A statement from the prescriber referencing the applicable ACR (American College of Rheumatology) guideline recommendation for belimumab in your patient's condition, without asserting specific numbers.

## Criteria-Mapping Structure

Obtain the exact indication language from the FDA-approved prescribing label for belimumab and from UnitedHealthcare's published Medical Policy for this drug. Then build a two-column table:

| Policy / Label Requirement | Chart Evidence That Satisfies It | |---|---| | Approved indication as stated in the label | Diagnosis code + specialist note confirming the indication | | Route and formulation authorized | Prescriber order matching the authorized route | | Any clinical-criteria qualifier in the UHC policy | Corresponding chart documentation |

Presenting this mapping explicitly — requirement by requirement — demonstrates that the denial rests on a documentation gap, not a true regulatory or clinical bar, and gives the reviewer a clear path to overturn.